RH Logo
Hubs
About
Live
Leaderboard

Most Reputable Users

Author Profile Avatar
Patrick Joyce
5785
Author Profile Avatar
Kranti Rumalla
933
Author Profile Avatar
Emeka A. Ezewudo
2819
Author Profile Avatar
ayotune adebayo
2246
Author Profile Avatar
Chukwuma Chidera
1413
Author Profile Avatar
Colin Moser
1267
Author Profile Avatar
Brian Armstrong
758
Author Profile Avatar
Precious Morgans
273
Author Profile Avatar
Kim Schult
232
Author Profile Avatar
Ian Hilgart
234

Trending Papers in covid-19

Trending
Today
339
From Paper: The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models
Published: Jan 2021
From Paper: The hyperlipidaemic drug fenofibrate significantly reduces infection by SARS-CoV-2 in cell culture models
Published: Jan 2021
The SARS-CoV-2 pandemic has caused a significant number of fatalities and worldwide disruption. To identify drugs to repurpose to treat SARS-CoV-2 infections, we established a screen to measure dimerization of ACE2, the primary receptor for the virus. This screen identified fenofibric acid, the active metabolite of fenofibrate. Fenofibric acid also destabilized the receptor binding domain (RBD) of the viral spike protein and inhibited RBD binding to ACE2 in ELISA and whole cell binding assays. Fenofibrate and fenofibric acid were tested by two independent laboratories measuring infection of cultured Vero cells using two different SARS-CoV-2 isolates. In both settings at drug concentrations which are clinically achievable, fenofibrate and fenofibric acid reduced viral infection by up to 70%. Together with its extensive history of clinical use and its relatively good safety profile, these studies identify fenofibrate as a potential therapeutic agent requiring urgent clinical evaluation to treat SARS-CoV-2 infection.
Author Profile Avatar
Chukwuma Chidera
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Chukwuma Chidera
313
From Paper: BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2
Published: Jan 2021
From Paper: BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2
Published: Jan 2021
  • SARS-CoV-2 infection of human cells is initiated by the binding of the viral Spike protein to its cell-surface receptor ACE2.
Author Profile Avatar
Chukwuma Chidera
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Chukwuma Chidera
7
Published: Jan 2021
Published: Jan 2021
The Covid-19 pandemic surges of 2020 resulted in major operational, personal, and financial impacts on US radiology practices. In response, a series o…
Author Profile Avatar
Colin Moser
5
Authors: Mulay, A., et al
Published: Jun 2020
Authors: Mulay, A., et al
Published: Jun 2020
Coronavirus disease 2019 (COVID-19) is the latest respiratory pandemic resulting from zoonotic transmission of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). Severe symptoms include viral pneumonia secondary to infection and inflammation of the lower respiratory tract, in some cases causing death. We developed primary human lung epithelial infection models to understand responses of proximal and distal lung epithelium to SARS-CoV-2 infection. Differentiated air-liquid interface cultures of proximal airway epithelium and 3D organoid cultures of alveolar epithelium were readily infected by SARS-CoV-2 leading to an epithelial cell-autonomous proinflammatory response. We validated the efficacy of selected candidate COVID-19 drugs confirming that Remdesivir strongly suppressed viral infection/replication. We provide a relevant platform for studying COVID-19 pathobiology and for rapid drug screening against SARS-CoV-2 and future emergent respiratory pathogens.
Author Profile Avatar
Precious Morgans
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Precious Morgans
6
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Precious Morgans
6
Authors: Agaoglu, Nihat Bugra, et al
Published: Jun 2020
Authors: Agaoglu, Nihat Bugra, et al
Published: Jun 2020
Author Profile Avatar
Precious Morgans
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Precious Morgans
6
Published: Sep 2020
Published: Sep 2020
Controlling for the polarity and subjectivity of social media data based on the development of the COVID-19 outbreak, we analyse the relationships bet…
Author Profile Avatar
Colin Moser
3
Authors: Hedde, Per Niklas, et al
Published: May 2020
Authors: Hedde, Per Niklas, et al
Published: May 2020
  • e
Author Profile Avatar
Precious Morgans
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Precious Morgans
3
Authors: Gniadek, Thomas J., et al
Published: Aug 2020
Authors: Gniadek, Thomas J., et al
Published: Aug 2020
We determined the antigen binding activity of convalescent plasma units from 47 individuals with a history of non-severe COVID-19 using three clinical diagnostic serology assays (Beckman, DiaSorin, and Roche) with different SARS-CoV-2 targets. We compared these results with functional neutralization activity using a fluorescent reporter strain of SARS-CoV-2 in a microwell assay. This revealed positive correlations of varying strength (Spearman r = 0.37-0.52) between binding and neutralization. Donors age 48-75 had the highest neutralization activity. Units in the highest tertile of binding activity for each assay were enriched (75-82%) for those with the highest levels of neutralization.
Author Profile Avatar
Precious Morgans
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Precious Morgans
3
Authors: Mulgaonkar, Nirmitee, et al
Published: Aug 2020
Authors: Mulgaonkar, Nirmitee, et al
Published: Aug 2020
The rapid geographic expansion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infectious agent of Coronavirus Disease 2019 (COVID-19) pandemic, poses an immediate need for potent drugs. Enveloped viruses infect the host cell by cellular membrane fusion, a crucial mechanism required for virus replication. The SARS-CoV-2 spike glycoprotein, due to its primary interaction with the human angiotensin-converting enzyme 2 (ACE2) cell-surface receptor, is considered as a potential target for drug development. Based on screening followed by studies, here we report that the existing FDA-approved Bcr-Abl tyrosine kinase inhibitor, imatinib, inhibits SARS-CoV-2 with an IC of 130 nM. We provide evidence that although imatinib binds to the receptor-binding domain (RBD) of SARS-CoV-2 spike protein with an affinity at micromolar, i.e., 2.32 ± 0.9 μM levels, imatinib does not directly inhibit the spike RBD:ACE2 interaction – suggesting a Bcr-Abl kinase-mediated fusion inhibition mechanism is responsible for the inhibitory action. We also show that imatinib inhibits other coronaviruses, SARS-CoV, and MERS-CoV via fusion inhibition. Based on promising results, we propose the Abl tyrosine kinase inhibitor (ATKI), imatinib, to be a viable repurposable drug against COVID-19.
Author Profile Avatar
Precious Morgans
Slide 1 of 1
  • Paper Preview Page 1
Author Profile Avatar
Precious Morgans
Load More Papers